Windward Bio Group AG

WWB
28.1711.15% ( -0.329 )
Trading: Nov 16, 13:37:37 (EDT)

Profile

About

Windward Bio Group AG
Windward Bio Group AG
WWB.US

Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease. The company has collaboration agreements with Sichuan Kelun-Biotech BioPharmaceutical Co., Ltd, Harbour BioMed (Shanghai) Co., Ltd, and Qyuns Therapeutics Co., Ltd. Windward Bio Group AG was incorporated in 2024 and is based in Basel, Switzerland.

Profile

Company Name
Windward Bio Group AG
Market
NasdaqGS
Founded
Industry
--
Fiscal Year End
--

Related Securities

Industry

Management